Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

GERN

Geron Corp

Feb 13 • 04:00PM ET

1.65

+0.02 1.23 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD FATE EXEL ACAD ONC PTCT ALLO ETON IMMP ATNM

| Held by: VTI XBI IWM VXF IWO IBB SCHA VTWO VHT ESML

Index	RUT	P/E	-	EPS (ttm)	-0.12	Insider Own	4.86%	Shs Outstand	638.36M	Perf Week	7.84%
Market Cap	1.05B	Forward P/E	-	EPS next Y	-0.03	Insider Trans	0.00%	Shs Float	607.35M	Perf Month	22.22%
Enterprise Value	922.13M	PEG	-	EPS next Q	-0.03	Inst Own	74.76%	Short Float	9.62%	Perf Quarter	33.06%
Income	-79.99M	P/S	5.74	EPS this Y	62.96%	Inst Trans	-1.71%	Short Ratio	6.15	Perf Half Y	13.79%
Sales	183.40M	P/B	4.24	EPS next Y	68.33%	ROA	-15.80%	Short Interest	58.46M	Perf YTD	25.00%
Book/sh	0.39	P/C	2.75	EPS next 5Y	-	ROE	-29.57%	52W High	2.84 -41.80%	Perf Year	-40.86%
Cash/sh	0.60	P/FCF	-	EPS past 3/5Y	8.65% 5.60%	ROIC	-16.68%	52W Low	1.04 58.65%	Perf 3Y	-38.89%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	280.92% 178.45%	Gross Margin	97.19%	Volatility	6.53% 6.41%	Perf 5Y	-14.06%
Dividend TTM	-	EV/Sales	5.03	EPS Y/Y TTM	62.68%	Oper. Margin	-34.40%	ATR (14)	0.09	Perf 10Y	-37.26%
Dividend Ex-Date	-	Quick Ratio	4.87	Sales Y/Y TTM	522.13%	Profit Margin	-43.61%	RSI (14)	69.58	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.96	EPS Q/Q	30.83%	SMA20	13.05%	Beta	0.57	Target Price	3.40
Payout	-	Debt/Eq	1.01	Sales Q/Q	67.05%	SMA50	19.19%	Rel Volume	1.33	Prev Close	1.63
Employees	229	LT Debt/Eq	0.93	Earnings	Feb 25 BMO	SMA200	22.91%	Avg Volume	9.50M	Price	1.65
IPO	Jul 31, 1996	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.66% -11.27%	Trades		Volume	12,595,501	Change	1.23%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-25	Resumed	Goldman	Sell	$1
May-08-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform	$1.50
Feb-27-25	Downgrade	B. Riley Securities	Buy → Neutral	$3.50 → $2
Feb-26-25	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-05-24	Initiated	H.C. Wainwright	Buy	$8
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-09-24	Initiated	Leerink Partners	Outperform	$7
Apr-30-24	Downgrade	Robert W. Baird	Outperform → Neutral	$4.50
Apr-29-24	Initiated	TD Cowen	Buy	$10
Mar-15-24	Reiterated	Needham	Buy	$4 → $5
Sep-12-23	Upgrade	Goldman	Neutral → Buy	$4
Mar-28-23	Initiated	Goldman	Neutral	$3
Oct-28-22	Initiated	Wedbush	Outperform	$5
Jul-28-22	Resumed	B. Riley Securities	Buy	$4
Nov-02-21	Initiated	Robert W. Baird	Outperform	$4
Feb-18-21	Resumed	B. Riley Securities	Buy	$4
Aug-03-20	Initiated	Stifel	Buy	$3
Nov-19-19	Resumed	B. Riley FBR	Buy	$4
Sep-03-19	Initiated	H.C. Wainwright	Buy	$4
Aug-15-19	Initiated	Cantor Fitzgerald	Overweight	$4

Show Previous Ratings

Feb-11-26 07:27AM	Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 (GlobeNewswire)
Jan-30-26 02:58PM	TD Cowen Maintains Buy Rating for Geron (GERN) While Trimming PT to $3 Ahead of Q4 Results (Insider Monkey)
Jan-18-26 12:29PM	Geron Corporation (GERN) Eyes Profitability in 2026 amid Restructuring Drive (Insider Monkey)
Jan-14-26 02:13PM	Geron Corporation (GERN) Streamlines Operations, Secures Financing, Eyes 2026 Growth (Insider Monkey)
Jan-12-26 08:00AM	Geron Corporation Provides 2026 Financial Guidance (GlobeNewswire) +6.72%
04:45AM	Loading…
Jan-07-26 04:45AM	Geron (GERN) Plans Restructuring to Cut Costs, H.C. Wainwright Stays Neutral (Insider Monkey)
Dec-18-25 04:30PM	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01:14AM	Geron Corporation (GERN) Restructuring to Lower Operating Expenses as it Eyes Profitability in 2026 (Insider Monkey)
Dec-12-25 05:18AM	Praxis tees up another approval filing; Geron turns to layoffs (BioPharma Dive)
Dec-11-25 11:40PM	Geron Corporation (GERN) Presents New Data at the 67th American Society of Hematology 2025 Annual Meeting (Insider Monkey) +8.59%
08:00AM	Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation (GlobeNewswire)
Dec-08-25 08:02AM	Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO (Imetelstat) in Lower-Risk MDS (GlobeNewswire)
Dec-04-25 12:20PM	Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points (PR Newswire)
Nov-24-25 09:47AM	Wall Street Turns Bullish on Geron Corporation (GERN) amid Rytelo Sales Push Plans (Insider Monkey)
Nov-05-25 04:04PM	Geron Corp (GERN) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst RYTELO Demand Challenges (GuruFocus.com) -5.22%
08:25AM	Loading…
08:25AM	Geron (GERN) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:19AM	Geron: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights (Business Wire)
Nov-04-25 08:00AM	Geron Corporation to Present at Upcoming Investor Conferences (Business Wire)
Nov-03-25 09:05AM	Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO (imetelstat) in Myeloid Hematologic Malignancies (Business Wire)
Oct-30-25 10:00AM	Arcellx, Inc. (ACLX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-29-25 10:00AM	Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-27-25 08:00AM	Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025 (Business Wire)
Oct-20-25 05:32PM	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.83%
Oct-13-25 04:34PM	Geron Corporation Announces Executive Leadership Transitions and Appointments (GlobeNewswire)
Sep-18-25 04:01PM	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
10:03AM	CG Oncology, Inc. (CGON) Moves 5.5% Higher: Will This Strength Last? (Zacks)
Aug-31-25 12:16AM	What Do Investors Think About Geron Corporation (GERN) Following Q2 Results? (Insider Monkey)
Aug-27-25 04:05PM	Geron to Participate in the 2025 Wells Fargo Healthcare Conference (Business Wire)
Aug-24-25 12:53AM	Needham Keeps Buy Rating on Geron (GERN) After Q2 Results (Insider Monkey)
11:45PM	Loading…
Aug-22-25 11:45PM	Leerink Partners Reiterates a Buy on Geron Corporation (GERN), Keeps the PT (Insider Monkey)
Aug-19-25 12:08AM	Geron Corporation (GERN) Announces Grant of Stock Options; Scotiabank Reiterates 'Hold' Rating (Insider Monkey)
Aug-18-25 04:01PM	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-17-25 11:41PM	Geron Corporation Names Harout Semerjian as New CEO to Lead Commercialization of RYTELO (Insider Monkey)
Aug-08-25 04:01PM	Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.25%
Aug-07-25 03:07AM	Geron Corp (GERN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements (GuruFocus.com) -6.47%
Aug-06-25 08:15AM	Geron (GERN) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +15.83%
07:13AM	Geron: Q2 Earnings Snapshot (Associated Press Finance)
07:01AM	Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights (Business Wire)
07:00AM	Geron Appoints Harout Semerjian as President and Chief Executive Officer (Business Wire)
Jul-29-25 08:20AM	Incyte (INCY) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
Jul-28-25 08:00AM	Geron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025 (Business Wire) -8.73%
Jul-18-25 04:05PM	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-15-25 08:58AM	Geron Presents Positive RYTELO Data for LR-MDS at ASCO & EHA, Highlights Efficacy, Myelofibrosis Program Progress (Insider Monkey) -5.97%
Jul-07-25 09:10AM	Leerink Partners Reiterates a Buy Rating on Geron Corporation (GERN) (Insider Monkey)
Jun-18-25 04:10PM	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.90%
May-28-25 08:30AM	Geron Announces Presentations at ASCO and EHA Underscoring RYTELO (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program (Business Wire)
May-19-25 04:15PM	Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +9.45%
May-13-25 08:55AM	Why Geron Corporation (GERN) Is The Best Low Priced Biotech Stock to Buy Now (Insider Monkey) -6.25%
May-08-25 03:07AM	Geron Corp (GERN) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges and Strategic ... (GuruFocus.com)
12:09AM	Q1 2025 Geron Corp Earnings Call (Thomson Reuters StreetEvents)
May-07-25 04:35PM	Why Geron Stock Crept Higher Today (Motley Fool)
12:51PM	Geron outlines strategies to boost RYTELO adoption and anticipates Phase III myelofibrosis trial results in 2026 (Seeking Alpha)
12:50PM	Geron Corporation (GERN) Q1 2025 Earnings Call Transcript (Seeking Alpha)
08:30AM	Geron (GERN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:27AM	Geron: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights (Business Wire)
04:07AM	GERN Securities Lawsuit Filed Against Geron Corporation- Contact the DJS Law Group to Discuss Your Rights (PR Newswire)
Apr-30-25 10:01AM	Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-24-25 12:27PM	Geron Corporation Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 12, 2025 to Discuss Your Rights GERN (GlobeNewswire)
Apr-18-25 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
11:45AM	Is Geron Corp. (NASDAQ:GERN) the Most Promising Penny Stock According to Analysts? (Insider Monkey)
Apr-16-25 10:02AM	Is Geron Corp. (NASDAQ:GERN) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey)
Apr-15-25 09:34AM	GERN Securities Lawsuit Filed Against Geron Corporation- Contact the DJS Law Group to Discuss Your Rights (PR Newswire) -5.30%
Apr-10-25 09:04AM	GERN Securities Lawsuit Filed Against Geron Corporation- Contact the DJS Law Group to Discuss Your Rights (PR Newswire) -6.47%
Apr-08-25 10:20AM	Should You Invest in Geron Corporation (GERN)? (Insider Monkey) -9.22%
Apr-07-25 08:00AM	ClearBridge Small Cap Growth Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-04-25 04:21AM	GERN Securities Lawsuit Filed Against Geron Corporation- Contact the DJS Law Group to Discuss Your Rights (PR Newswire) -6.12%
Mar-31-25 04:32PM	Geron Corp.: A Compelling Potential Buying Opportunity Thanks To Bearish Comments (Seeking Alpha) -6.92%
04:30PM	Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025 (Business Wire)
02:34PM	Biotech Stocks Q1 2025 Recap: Winners And Underperformers (Seeking Alpha)
Mar-28-25 09:30AM	GERN Securities Lawsuit Filed Against Geron Corporation- Contact the DJS Law Group to Discuss Your Rights (PR Newswire)
Mar-25-25 05:52PM	Geron Corporation Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - GERN (PR Newswire)
05:43PM	Is Geron Corporation (NASDAQ:GERN) The Top Penny Stock That Will Skyrocket? (InsiderMonkey)
Mar-21-25 01:43PM	Geron Corporation Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 12, 2025 to Discuss Your Rights GERN (GlobeNewswire)
Mar-19-25 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-18-25 05:45AM	Shareholders of Geron Corporation Should Contact Levi & Korsinsky Before May 12, 2025 to Discuss Your Rights - GERN (PR Newswire)
Mar-11-25 04:30PM	Geron Announces European Commission Approval of RYTELO (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS (Business Wire) +10.62%
04:02PM	Geron Corporation Announces Departure of Chief Executive Officer (Business Wire)
Feb-26-25 07:30AM	Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (Business Wire) -32.07%
Feb-21-25 09:00AM	Geron to Participate at Upcoming Investor Conferences in March 2025 (Business Wire)
Feb-19-25 04:15PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-03-25 09:00AM	Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025 (Business Wire)
Jan-21-25 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-28-24 09:52AM	Geron Corp. (GERN) Ends Trading Week Defying Market Bloodbath (Insider Monkey)
Dec-19-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-14-24 06:40AM	Geron announces positive CHMP opinion for Rytelo (TipRanks)
Dec-13-24 06:36AM	Geron Announces Positive CHMP Opinion for RYTELO (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS (Business Wire)
Dec-10-24 09:00AM	Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis (Business Wire)
09:00AM	Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies (Business Wire)
Nov-27-24 09:00AM	Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-21-24 04:30PM	Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-11-24 04:30PM	Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development (Business Wire)
09:00AM	Geron to Participate in the Stifel 2024 Healthcare Conference (Business Wire)
Nov-08-24 07:29AM	Geron Secures $250M Funding and Strong Q3 Sales (TipRanks)
Nov-07-24 07:10AM	Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million (GlobeNewswire)
07:01AM	Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors (Business Wire)
07:00AM	Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
Nov-05-24 09:00AM	Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO (imetelstat) in Myeloid Hematologic Malignancies (Business Wire)

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
JAMES ZIEGLER	Officer	Dec 15 '25	Proposed Sale	1.37	20,000	27,400		Dec 15 05:33 PM
LAWLIS V BRYAN	Director	May 09 '25	Buy	1.18	13,300	15,667	13,300	May 13 04:20 PM
Samuels Scott Alan	EVP, Chief Legal Officer	Feb 27 '25	Buy	1.61	15,000	24,150	26,682	Mar 03 06:01 AM
SCARLETT JOHN A	Chairman, President and CEO	Feb 27 '25	Buy	1.76	12,500	22,062	12,500	Mar 03 06:01 AM
Ziegler James	EVP, Chief Commercial Officer	Feb 27 '25	Buy	1.60	100,000	160,000	100,000	Mar 03 06:01 AM

Open in Screener

BMRN

Biomarin Pharmaceutical Inc

Feb 13 • 04:00PM ET

59.87

-0.07 -0.12 %

Healthcare • Biotechnology • USA • NASD

BMRN Biomarin Pharmaceutical Inc daily Stock Chart

Peers: REGN VRTX SRPT NBIX ALNY BLUE IONS RARE EXEL PRTA

| Held by: IJH VTI VB VBK VXF XBI MDY IBB FBT SPMD

Index	-	P/E	22.43	EPS (ttm)	2.67	Insider Own	1.10%	Shs Outstand	192.10M	Perf Week	2.99%
Market Cap	11.50B	Forward P/E	14.37	EPS next Y	4.17	Insider Trans	0.00%	Shs Float	190.00M	Perf Month	6.76%
Enterprise Value	10.64B	PEG	0.39	EPS next Q	0.21	Inst Own	95.12%	Short Float	4.16%	Perf Quarter	8.22%
Income	520.42M	P/S	3.73	EPS this Y	2.64%	Inst Trans	-1.68%	Short Ratio	2.94	Perf Half Y	3.22%
Sales	3.09B	P/B	1.90	EPS next Y	83.74%	ROA	7.20%	Short Interest	7.91M	Perf YTD	0.74%
Book/sh	31.53	P/C	7.78	EPS next 5Y	36.60%	ROE	9.07%	52W High	73.51 -18.56%	Perf Year	-7.06%
Cash/sh	7.69	P/FCF	13.82	EPS past 3/5Y	- -	ROIC	7.82%	52W Low	50.76 17.95%	Perf 3Y	-45.08%
Dividend Est.	-	EV/EBITDA	11.34	Sales past 3/5Y	15.43% 10.98%	Gross Margin	80.64%	Volatility	3.79% 2.91%	Perf 5Y	-31.22%
Dividend TTM	-	EV/Sales	3.45	EPS Y/Y TTM	60.21%	Oper. Margin	27.73%	ATR (14)	1.79	Perf 10Y	-14.57%
Dividend Ex-Date	-	Quick Ratio	3.10	Sales Y/Y TTM	12.31%	Profit Margin	16.87%	RSI (14)	60.83	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	4.83	EPS Q/Q	-129.25%	SMA20	4.04%	Beta	0.25	Target Price	88.59
Payout	0.00%	Debt/Eq	0.10	Sales Q/Q	5.98%	SMA50	5.02%	Rel Volume	0.72	Prev Close	59.94
Employees	3040	LT Debt/Eq	0.10	Earnings	Oct 27 AMC	SMA200	5.91%	Avg Volume	2.69M	Price	59.87
IPO	Jul 23, 1999	Option/Short	Yes / Yes	EPS/Sales Surpr.	42.88% -0.17%	Trades		Volume	1,939,845	Change	-0.12%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Resumed	Barclays	Overweight	$80
Jan-20-26	Upgrade	Canaccord Genuity	Hold → Buy	$98
Dec-03-25	Downgrade	Leerink Partners	Outperform → Market Perform	$60
Nov-06-25	Downgrade	Stifel	Buy → Hold	$61
Sep-08-25	Initiated	H.C. Wainwright	Neutral	$60
Sep-03-25	Initiated	Raymond James	Outperform	$85
Jul-03-25	Resumed	Morgan Stanley	Overweight	$97
Feb-24-25	Upgrade	Oppenheimer	Perform → Outperform	$98
Nov-15-24	Initiated	Wolfe Research	Outperform	$95
Oct-30-24	Downgrade	William Blair	Outperform → Mkt Perform
Oct-10-24	Resumed	Raymond James	Outperform	$79
Aug-20-24	Upgrade	Bernstein	Mkt Perform → Outperform	$94 → $110
May-17-24	Downgrade	Robert W. Baird	Outperform → Neutral	$104 → $72
May-14-24	Initiated	Evercore ISI	Outperform	$113
Nov-15-23	Initiated	Wells Fargo	Overweight	$100
Oct-23-23	Upgrade	Bernstein	Underperform → Mkt Perform	$82
Sep-28-23	Initiated	Raymond James	Mkt Perform
Sep-18-23	Initiated	UBS	Buy	$120
Jul-27-23	Initiated	Scotiabank	Sector Perform	$95
Jul-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$102

Show Previous Ratings

Feb-13-26 04:31PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
Feb-12-26 04:05PM	BioMarin Announces Closing of Private Offering of Senior Notes (PR Newswire)
12:44PM	BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 (Benzinga)
10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-11-26 10:00AM	Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline (Zacks)
08:30AM	Loading…
08:30AM	Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? (Zacks)
Feb-08-26 03:49AM	What Does the Street Think About BioMarin Pharmaceutical Inc. (BMRN)? (Insider Monkey)
Feb-07-26 04:09AM	Acquisition Plans to Fuel BioMarin Pharmaceutical (BMRN), According to Barclays (Insider Monkey)
Jan-31-26 05:04AM	Should You Buy BioMarin Pharmaceutical Before Feb. 18? (Motley Fool)
Jan-29-26 04:05PM	BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility (PR Newswire)
Jan-28-26 11:24AM	FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside? (Zacks)
06:57AM	Upcoming Acquisition Resulting in Bullish Stance on BioMarin Pharmaceutical (BMRN) (Insider Monkey)
Jan-27-26 07:22AM	Double-digit Revenue Growth Till 2030 Drives BioMarin's (BMRN) Bullish Thesis (Insider Monkey)
Jan-26-26 07:45AM	BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility (PR Newswire)
Jan-22-26 06:02AM	BioMarin vets form Mendra to modernize rare disease drug development (BioPharma Dive)
11:01AM	Loading…
Jan-16-26 11:01AM	FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock? (Zacks)
09:50AM	Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term (Zacks)
Jan-15-26 10:08AM	Zacks.com featured highlights include Universal Health Services, PNC Financial Services, Global Payments and BioMarin Pharmaceutical (Zacks)
08:47AM	Buy These 5 Price-to-Book Value Stocks for Gains in 2026 (Zacks)
Jan-14-26 12:25PM	Humana Partners With Atlas to Enhance Cancer Care for Seniors (Zacks)
08:52AM	4 Value Stocks to Buy As Wall Street Weighs Trump Policies (Zacks)
Jan-13-26 11:40AM	BMRN or TARS: Which Is the Better Value Stock Right Now? (Zacks)
09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
09:40AM	Is BioMarin Pharmaceutical (BMRN) a Great Value Stock Right Now? (Zacks)
05:46AM	BioMarin Pharmaceutical touts $3.2B 2025 revenue, Voxzogo surge and Amicus deal at JPM Conference (MarketBeat)
Jan-12-26 04:05PM	BioMarin Appoints Arpit Dave Chief Digital and Information Officer (PR Newswire)
09:40AM	Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term (Zacks)
Jan-08-26 04:05PM	BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA (PR Newswire)
08:30AM	Veeva and BioMarin Form Long-Term Strategic Partnership (PR Newswire)
Jan-05-26 04:26AM	10 Magnificent Stocks That Can Make You Richer in 2026 (Motley Fool)
06:29AM	Loading…
Jan-01-26 06:29AM	H.C. Wainwright: BioMarin's (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver (Insider Monkey)
Dec-30-25 11:54AM	Is BioMarin Pharmaceutical Inc. (BMRN) the Ridiculously Cheap Stock to Buy Now? (Insider Monkey)
Dec-29-25 09:30PM	Rocket Lab, Micron, And CoreWeave Are Among the Top 10 Large-Cap Gainers Last Week (Dec. 22-Dec. 26): Are the Others in Your Portfolio? (Benzinga)
07:52AM	Here Are Mondays Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More (24/7 Wall St.)
Dec-24-25 06:30AM	Spruce Biosciences initiated with an Outperform at Oppenheimer (TipRanks)
Dec-23-25 02:35PM	BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know (StockStory)
Dec-22-25 10:18PM	Analysts Grow More Bullish on BioMarin Pharmaceuticals Inc. (BMRN) After Amicus Acquisition (Insider Monkey)
09:09PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
12:27PM	BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push (Pharmaceutical Technology)
12:15PM	A $4.8 Billion Reason to Buy BioMarin Stock Today (Barchart)
11:46AM	BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B (Zacks)
Dec-20-25 08:13AM	BioMarin (BMRN) Jumps 17.7% on $5-Billion Merger with Amicus (Insider Monkey)
Dec-19-25 04:32PM	Stocks to Watch Friday Recap: Lamb Weston, Intuitive Machines, Nike, Oracle (The Wall Street Journal) +17.71%
04:17PM	BioMarin Soars 18% After Folding In The $4.8 Billion Takeover Of Amicus (Investor's Business Daily)
04:16PM	Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today (StockStory)
12:41PM	Biotech Bombshell: BioMarin's $4.8B Bet Ignites Amicus Shares in Rare-Disease Power Play (GuruFocus.com)
11:57AM	BioMarin to Buy Rare-Disease Biotech Amicus Therapeutics for $4.8 Billion (The Wall Street Journal)
11:01AM	Stocks to Watch Friday: Lamb Weston, Intuitive Machines, Nike, Oracle (The Wall Street Journal)
10:55AM	BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping. (Barrons.com)
09:38AM	Stocks to Watch Friday: Nike, Oracle, FedEx, Sony (The Wall Street Journal)
09:06AM	BioMarin Pharmaceutical Scoops Up Amicus Therapeutics In $4.8 Billion Deal (Investor's Business Daily)
08:13AM	BioMarin to Buy Amicus Therapeutics for $4.8 Billion (The Wall Street Journal)
07:45AM	BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook (PR Newswire)
Dec-15-25 01:16PM	Do Options Traders Know Something About BMRN Stock We Don't? (Zacks)
Dec-11-25 07:44AM	Leerink Cuts BioMarin Pharmaceutical Inc. (BMRN) Price Target to $60, Citing Valuation and Competitive Challenges (Insider Monkey)
Dec-10-25 10:32AM	BioMarin Pharmaceutical Inc. (BMRN) Outlook Lowered By Leerink (Insider Monkey)
Dec-04-25 02:15PM	BioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory (Insider Monkey)
Dec-03-25 11:30AM	Why Is Xenon Pharmaceuticals (XENE) Up 9.7% Since Last Earnings Report? (Zacks)
Nov-27-25 11:30AM	Why Is Alkermes (ALKS) Down 5.5% Since Last Earnings Report? (Zacks)
Nov-24-25 11:00PM	2 Reasons to Like BMRN and 1 to Stay Skeptical (StockStory)
Nov-23-25 10:33PM	Q3 Earnings Outperformers: BioMarin Pharmaceutical (NASDAQ:BMRN) And The Rest Of The Therapeutics Stocks (StockStory)
Nov-20-25 11:02PM	BioMarin Pharmaceutical (BMRN): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
06:57AM	Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. (Motley Fool)
Nov-11-25 09:00AM	BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England (PR Newswire)
Nov-04-25 09:36AM	J.P. Morgan Reiterates a Buy Rating on BioMarin Pharmaceutical (BMRN) (Insider Monkey)
Nov-03-25 12:31AM	The 5 Most Interesting Analyst Questions From BioMarin Pharmaceutical's Q3 Earnings Call (StockStory)
Oct-31-25 10:28PM	Morgan Stanley Maintains Buy on BioMarin Pharmaceutical (BMRN) (Insider Monkey)
Oct-30-25 09:39PM	BioMarin Pharmaceutical (BMRN) Announces Financial Results for Q3 2025 (Insider Monkey)
Oct-29-25 06:11PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
09:00AM	FDA Accepts BioMarin's PALYNZIQ (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria (PR Newswire)
Oct-28-25 04:59PM	Why BioMarin Pharmaceutical Stock Topped the Market on Tuesday (Motley Fool)
02:26PM	BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy (Zacks)
12:24PM	Why is BioMarin Pharmaceutical (BMRN) One of the Most Profitable Biotech Stocks to Buy? (Insider Monkey)
12:10PM	Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today (StockStory)
01:31AM	BMRN Q3 Deep Dive: Product Expansion and Portfolio Shifts Define Outlook (StockStory)
Oct-27-25 11:00PM	BioMarin Pharmaceutical Inc (BMRN) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
06:00PM	Compared to Estimates, BioMarin (BMRN) Q3 Earnings: A Look at Key Metrics (Zacks)
05:30PM	BioMarin Pharmaceutical (BMRN) Tops Q3 Earnings Estimates (Zacks)
04:32PM	BioMarin: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	BioMarin Pharmaceutical (NASDAQ:BMRN) Posts Q3 Sales In Line With Estimates (StockStory)
04:03PM	BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update (PR Newswire)
01:55PM	BioMarin, following sluggish sales, to offload hemophilia gene therapy (BioPharma Dive)
Oct-25-25 11:03PM	BioMarin Pharmaceutical (BMRN) Reports Q3: Everything You Need To Know Ahead Of Earnings (StockStory)
Oct-24-25 12:43AM	3 of Wall Street's Favorite Stocks to Target This Week (StockStory)
Oct-23-25 10:00AM	Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-22-25 04:05PM	BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET (PR Newswire)
Oct-17-25 09:54PM	Cantor Fitzgerald Reiterates a Buy Rating for BioMarin Pharmaceutical (BMRN) (Insider Monkey)
Oct-08-25 12:57AM	Where is BioMarin Pharmaceutical (BMRN) Headed According to Analysts? (Insider Monkey)
Oct-06-25 09:40AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock (Zacks)
Oct-02-25 09:46AM	Growth and Pipeline Keep BioMarin Pharmaceutical Inc. (BMRN) Attractive for Investors (Insider Monkey)
Oct-01-25 08:08PM	BioMarin Pharmaceutical Inc. (BMRN) Hits Its 52-Week Low (Insider Monkey)
09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
Sep-30-25 04:01AM	Raymond James Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN), Sets a $85 PT (Insider Monkey)
Sep-19-25 09:40AM	Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term (Zacks)
Sep-18-25 12:39PM	BioMarin Pharmaceutical Inc.'s (BMRN) Phenylketonuria Candidate Drug Impresses in Phase 3 Trials (Insider Monkey)
Sep-17-25 02:27PM	BMO Capital Reiterates a Buy on BioMarin Pharmaceutical (BMRN) (Insider Monkey)
Sep-16-25 12:37PM	BioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory (Insider Monkey)
09:51AM	New Study Results Highlight BioMarin's VOXZOGO Efficacy in Children (Insider Monkey)
Sep-15-25 11:31PM	Reflecting On Therapeutics Stocks' Q2 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) (StockStory)
09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burkhart Erin	GVP, Chief Accounting Officer	May 20 '25	Sale	59.31	1,786	105,928	14,173	May 20 05:58 PM
Burkhart Erin	Officer	May 20 '25	Proposed Sale	59.31	1,786	105,928		May 20 09:58 AM
Hubbard Cristin	EVP, Chief Commercial Officer	May 02 '25	Sale	64.92	273	17,723	32,700	May 06 05:07 PM
Hubbard Cristin	Officer	May 02 '25	Proposed Sale	64.92	273	17,723		May 02 10:05 AM
Burkhart Erin	GVP, Chief Accounting Officer	Mar 19 '25	Sale	71.52	1,295	92,618	16,955	Mar 20 07:38 PM
Burkhart Erin	Officer	Mar 19 '25	Proposed Sale	71.52	1,295	92,618		Mar 19 09:36 AM
Guyer Charles Greg	EVP, Chief Technical Officer	Mar 06 '25	Sale	71.28	7,034	501,355	87,655	Mar 07 04:06 PM
Guyer Charles Greg	Officer	Mar 06 '25	Proposed Sale	71.28	7,034	501,359		Mar 06 04:05 PM
Burkhart Erin	GVP, Chief Accounting Officer	Feb 24 '25	Sale	68.38	1,344	91,903	13,105	Feb 25 08:21 PM
Burkhart Erin	Officer	Feb 24 '25	Proposed Sale	68.38	1,344	91,903		Feb 24 10:26 AM

GERN

Geron Corp

BMRN

Biomarin Pharmaceutical Inc

Upgrade your FINVIZ experience